Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials
Amgen Ventures-backed AAVantgarde Bio has raised $141 million in series B funding that the Italian biotech will use to push its two eye disease gene therapies through the clinic. One…